ConductScience.org, home

Paper29664018

Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Zheng X and 19 others. J Clin Invest, 2018. Cited by 210 papers, by iCite.

Cite this record

ConductScience Library. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Papers, record 29664018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29664018

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.
PubMed
Journal
J Clin Invest
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
210
iCite
Relative citation ratio, by iCite
6.09
iCite
Revised in PubMed
2019-09-11
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zheng XXichen
2Fang ZZhaoxu
3Liu XXiaomei
4Deng SShengming
5Zhou PPei
6Wang XXuexiang
7Zhang CChenglin
8Yin RRongping
9Hu HHaitian
10Chen XXiaolan
11Han YYijie
12Zhao YYun
13Lin SHSteven H
14Qin SSongbing
15Wang XXiaohua
16Kim BYBetty Ys
17Zhou PPenghui
18Jiang WWen
19Wu QQingyu
20Huang YYuhui

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CD8-Positive T-LymphocytesMajor topic
Colonic NeoplasmsMajor topic
Lymphocyte DepletionMajor topic
Mammary Neoplasms, ExperimentalMajor topic
PerfusionMajor topic
Animals
Interferon-gamma
Mice

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER
R01 NS104315NINDS NIH HHSUnited StatesR01NS104315PubMed and NIHNIH RePORTER

Download CSV of grants

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116916931A2A adenosine receptor protects tumors from antitumor T cells.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16916931PubMed
224990240Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.Cancer Immunol Res2014https://conductscience.org/library/papers/24990240PubMed
318418378Vascular normalization in Rgs5-deficient tumours promotes immune destruction.Nature2008https://conductscience.org/library/papers/18418378PubMed
422205687Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.Clin Cancer Res2012https://conductscience.org/library/papers/22205687PubMed
526936508PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.Sci Transl Med2016https://conductscience.org/library/papers/26936508PubMed
624190997Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/24190997PubMed
726433815PD-L1 expression as a potential predictive biomarker.Lancet Oncol2015https://conductscience.org/library/papers/26433815PubMed
827079802Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer2016https://conductscience.org/library/papers/27079802PubMed
920516446Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol2010https://conductscience.org/library/papers/20516446PubMed
1015701862Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.Clin Cancer Res2005https://conductscience.org/library/papers/15701862PubMed
1115637262Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science2005https://conductscience.org/library/papers/15637262PubMed
1225765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
1322658127Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012https://conductscience.org/library/papers/22658127PubMed
1423390376CTLA-4 blockade in tumor models: an overview of preclinical and translational research.Cancer Immun2013https://conductscience.org/library/papers/23390376PubMed
1519201652T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.Trends Immunol2009https://conductscience.org/library/papers/19201652PubMed
1622547817Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22547817PubMed
1725307346Interferon-γ safeguards blood-brain barrier during experimental autoimmune encephalomyelitis.Am J Pathol2014https://conductscience.org/library/papers/25307346PubMed
1828046063Three-Dimensional High-Frequency Ultrasonography for Early Detection and Characterization of Embryo Implantation Site Development in the Mouse.PLoS One2017https://conductscience.org/library/papers/28046063PubMed
1923752227Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.J Exp Med2013https://conductscience.org/library/papers/23752227PubMed
2025838373The future of immune checkpoint therapy.Science2015https://conductscience.org/library/papers/25838373PubMed

See all 46 referencesDownload CSV of references

Cited by160

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.

PMIDTitleJournalYearIn PapersSource
42957962Human Intravital Microscopy.Methods Mol Biol2027https://conductscience.org/library/papers/42957962PubMed
42806957Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy.J Transl Res2026https://conductscience.org/library/papers/42806957PubMed
42538573CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model.Cancer Imaging2026https://conductscience.org/library/papers/42538573PubMed
42505204
Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.
Curr Oncol2026https://conductscience.org/library/papers/42505204PubMed
42396187
Anlotinib Combined with Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 9 Hydrochloride Suppresses Colorectal Cancer Progression by Inducing Neovascularization and Reprogramming the Tumor Immune Microenvironment in MSS Murine Model.
Immunotargets Ther2026https://conductscience.org/library/papers/42396187PubMed
42312195Identification of chondroitin polymerizing factor as a biomarker for predicting immunotherapy response in breast cancer: a bioinformatics analysis of tumor microenvironment.Transl Cancer Res2026https://conductscience.org/library/papers/42312195PubMed
42204346Poorly perfused tumor regions harbor T cells with a glucose-dependent effector phenotype.EMBO Rep2026https://conductscience.org/library/papers/42204346PubMed
41997128Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature.Cell2026https://conductscience.org/library/papers/41997128PubMed
41808840Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation.Front Immunol2026https://conductscience.org/library/papers/41808840PubMed
41692709Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases.BMC Cancer2026https://conductscience.org/library/papers/41692709PubMed
41673720Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors.Breast Cancer Res2026https://conductscience.org/library/papers/41673720PubMed
41665856A mechanical reprogramming: synergistic tumor microenvironment normalization improves nano-immunotherapy delivery in prostate cancer via multiphysics modeling.Drug Deliv Transl Res2026https://conductscience.org/library/papers/41665856PubMed
41584574Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer.Front Oncol2025https://conductscience.org/library/papers/41584574PubMed
41556173Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy.Int J Surg2026https://conductscience.org/library/papers/41556173PubMed
41402130Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.Future Oncol2026https://conductscience.org/library/papers/41402130PubMed
41358269Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review).Oncol Lett2026https://conductscience.org/library/papers/41358269PubMed
41313745Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41313745PubMed
41229377Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41229377PubMed
41133010Multi-institutional development and validation of habitat imaging for predicting outcomes of first-line immunotherapy in advanced non-small cell lung cancer.Transl Lung Cancer Res2025https://conductscience.org/library/papers/41133010PubMed
40579467Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.Nat Rev Immunol2025https://conductscience.org/library/papers/40579467PubMed

See all 160 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29664018

GET https://conductscience.org/api/papers/v1/29664018/references?page=2